A multicenter, cross‐sectional analysis to assess the safety and usage pattern of brivaracetam in the management of partial‐onset seizure with BAEs—BREEZE study: A post‐hoc analysis
Abstract Objective Brivaracetam (BRV), a third‐generation anti‐seizure medication (ASM) offers strong conformational receptor domain binding, faster blood brain barrier (BBB) permeability and better tolerability making it potential therapeutic option as an initial line or initial line add‐on strateg...
Saved in:
Main Authors: | Arvind Sharma, Krishnaprasad Korukonda, Amit Haldar, Usha Kant Misra, R. V. Anand, Yakshdeep Dave, Girish Kulkarni |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2025-02-01
|
Series: | Epilepsia Open |
Subjects: | |
Online Access: | https://doi.org/10.1002/epi4.13065 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A meta-analytic evaluation of the efficacy and safety of levetiracetam for treating myoclonic seizures
by: Sara Najafi, et al.
Published: (2025-02-01) -
Brivaracetam to Treat Partial Onset Seizures in Adults
by: Dustin Latimer, et al.
Published: (2023-01-01) -
Usefulness of perampanel as initial monotherapy in children with non-lesional focal epilepsy
by: Hideaki Kanemura, et al.
Published: (2025-03-01) -
Clinical and genetic analysis of epilepsy with myoclonic-atonic seizures caused by SLC6A1 gene variant
by: Zhen Li, et al.
Published: (2025-01-01) -
New-onset seizure in pregnancy: case report and literature review
by: I. Paulauskienė, et al.
Published: (2022-03-01)